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Abstract 
Sudden cardiac death (SCD) is one of the most important mode of death in Western 
Countries and remains a major public health problems; is responsible for half of all deaths 
due to cardiovascular disease. New methods of preventing potentially fatal arrhythmias 
have been developed, and the accurate diagnosis of the causes of Sudden Cardiac Death 
is now of particular importance. In recent years researchers have identified the genetic 
background of many diseases involving the myocardium, and many Cardiomyopathies 
are considered to have a genetic origin. Autopsy and genetic family screening remains of 
great importance, not only in the research setting but also for clinical testing and should 
be performed when ever possible. The adequate assessment of Sudden Cardiac Death, 
including not only a protocol for heart examination and histological sampling, but also 
for toxicology and molecular genetic investigation. 
Sudden deaths involving young individuals (< 35 years of age) remain unexplained 
following a complete medicolegal investigation that includes an autopsy. Cardiac 
channelopathies associated with structurally normal hearts such as long QT syndrome 
(LQTS), catecholaminergic polymorphic ventricular tachycardia (CPVT), and Brugada 
syndrome (BrS), leave no evidence to be found at autopsy, leaving investigators to only 
speculate that a lethal arrhythmia might lie at the heart of a sudden unexplained death 
(SUD). 
In cases of autopsy negative SUD, continued investigation, through the use of a 
cardiological and genetic evaluation of first- or second-degree relatives and/or a 
molecular autopsy, may pinpoint the underlying mechanism attributing to the sudden 
death and allow for the identification of living family members with the pathogenic 
substrate that renders them vulnerable to an increased risk for cardiac events, including 
sudden death.1                   
 
 
 
                                                             
1 Nicole J. Boczek, David J. Tester and Michael J. Ackerman. The molecular autopsy: an indispensable 
step following sudden cardiac death in the young?. Herzschrittmacherther Elektrophysiol. 2012 September 
; 23(3): . doi:10.1007/s00399-012-0222-x. 
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Introduction 
Sudden cardiac death (SCD) is defined as an unexpected and non-traumatic death of an 
individual who had been observed healthy in previous 6 hours of the death. In western 
countries, SCD underlies 20% of total mortality.2 Although heart failure and coronary 
artery disease are the most prevalent substrates, epidemiological studies indicate that 
monogenic syndromes – called inherited arrhythmogenic diseases - also plays an 
important role in cardiac electrical instability. Thus, the inherited arrhythmogenic 
diseases have been defined broadly as 2 categories of pathologies: channelopathies and 
cardiomyopathies. Channelopathies are caused by pathogenic variations in genes 
encoding ion channels, and include Long QT Syndrome (LQTS), Brugada Syndrome 
(BrS), Short QT Syndrome (SQTS), and Catecholaminergic Polymorphic Ventricular 
Tachycardia (CPVT).3 Cardiomyopathies results from variations in genes encoding 
sarcomeric, cytoskeletal, and desmosomal proteins, and include Hypertrophic 
Cardiomyopathy (HCM), Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), 
and Dilated Cardiomyopathy (DCM).4 
In Europe, sudden cardiac death (SCD) is one of the most common causes of death in 
infants, children and young adults and is relatively rare, with an incidence of 1 to 5 per 
100.000 persons per year. 5 
Sudden death has been defined as “a natural, unexpected fatal event occurring within 
one hour from the onset of symptoms in apparently healthy subject or whose disease was 
not so severe as to predict an abrupt outcome”6       
                                                             
2 Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients 
with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College 
of Cardiology/ American Heart Association Task Force and the European Society of Cardiology Committee 
for Practice Guidelines (writing committee to develop guidelines for management of patients with 
ventricular arrhythmias and the prevention of sudden cardiac death): developed in collaboration with the 
European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006;114:e385– e484. 
3 Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task force on sudden cardiac death, European Society 
of Cardiology. Europace 2002;4:3–18. 
4 O. Campuzano, C. Allegue, A. Fernandez, A. Iglesias, R. Brugada. Determining the Pathogenicity of 
Genetic Variants Associated with Cardiac Channelopathies. Scientific Reports 5:7953 DOI: 
10.1038/srep07953. 
5 S. Kauferstein, N. Kiehne et al, 2009. Cardiac gene defects can cause sudden cardiac death in young 
people. Deutsches Arzteblatt International 2009; 106(4): 41-7. 
6 Goldstein S (1982). The necessity of a uniform definition of sudden coronary death: witnessed death 
within 1 hour of the onset of acute symptoms. Am Heart J 103:156-159.  
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Sudden Arrhythmic Death Syndrome (SADS) is defined as sudden unexpected death with 
no previous cardiac history, last seen alive within 12 hours of being found dead and with 
no cause identifiable on postmortem examination (including negative toxicology and 
ideally an expert cardiac pathologist review)7; is responsible about 1 million deaths 
annually in the developed world, which makes arrhythmias as one of the most significant 
causes of death and disease in the general population.8 
The underlying substrate varies: ischemic Heart disease in 75-80% cases; idiopathic 
cardiomyopathy in 10-15%; and 1-2% due to rare monogenic mutation in cardiac ion 
channel or associated proteins9.                                                                                                                                                                                                                                      
Cardiomyopathy were defined as primary myocardial disorders of unknown cause: 
primary is used to describe diseases in which the heart is the sole or predominantly 
involved organ; secondary to describe diseases in which myocardial dysfunction is part 
of a systemic disorder. 
Cardiomyopathies are grouped into specific morphological and functional phenotypes; 
each phenotype in then sub-classified into familial and non familial forms. The expert 
panel of the American Heart Association has suggested that ion channelopathies and 
disorders of conduction should also be considered as cardiomyopathies10. 
When the cause is not readily identifiable by the common investigations (coronary 
angiography and transthoracic echocardiography or by autopsy) the cause of the cardiac 
arrest is termed “unexplained”. Unexplained cardiac arrest is defined as a cardiac arrest 
in the absence of coronary artery disease and overt structural heart disease, present in 5%-
10% of cardiac arrest survivors. In the young, in up to 50% of sudden cardiac death cases, 
sudden death is the first and only clinical manifestation of an inherited cardiac disease 
that had remained undetected by conventional clinical investigations. The autopsy 
becomes the principal diagnostic tool because macroscopic and microscopic analyses 
                                                             
7L M Nunn, P D Lambiase, 2011. Genetics and cardiovascular diseasedcauses and prevention of 
unexpected sudden adult death: the role of the SADS clinic. Heart, vol. 97 pag1122-1127. 
8Campuzano O. et al, 2010. Genetics and cardiac channelopathies.  Genet Med.;12 (5):260-7. 
9Chopra N. et al, 2011. “Genetics of sudden cardiac death syndromes”. Curr Opin Cardiol 26:196-203. 
10Elliot P. et al, 2008. “Classification of the cardiomyopathies: a posit ion statement from the European 
society of cardiology working gr                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
oup on myocardial and pericardial diseases”. European Heart Journal, 29, 270-276. 
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reveal the underlying cause of death. However, a significant number of sudden cardiac 
deaths remain unexplained.11      
A genetic contribution to cardiac arrest is more common in this population, most 
commonly attributed to an inherited ion channel abnormality leading to familial syncope 
and sudden death12. 
The goal of this study was to examine blood samples from patients with cardiac 
syndromes and formalin-fixed paraffin embedded tissue  (FF-PET) cases of sudden 
cardiac death autopsy, to verify the corresponding genetic mutations and in particular the 
Ion channel disease. 
Ion channels are integral membrane proteins that are responsible for ion conduction 
across the cell membrane. Ion channel subunits are multimeric proteins formed by 
different subunits, which are usually encoded by separate genes. Ion channel subunits are 
formed by pore-forming α-subunits, which mediate ion currents, and regulatory β-
subunits. Channelopathy is thus defined as an inherited syndrome caused by mutations in 
genes encoding for ion channels, their subunits, or associated proteins. Genetic studies 
may be key to providing a lead toward an etiology for the unexplained symptoms. 
There are several mutations that can affect the ion channels. The effects of these mutations 
can be grouped in three: alteration of the channel’s permeability, alteration of the 
channel’s activation, and dysfunction of the channel’s inactivation. 
Genetic testing is becoming an important tool for a personalized medical approach to 
Cardiomyopathies. Autopsy and genetic family screening remains of great importance, 
not only in the research setting but also for clinical testing and should be performed when 
ever possible13. 
 
 
                                                             
11 7. Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the 
cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical 
Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and 
Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on 
Epidemiology and Prevention. Circulation 2006;113:1807–1816. 
12 Matthew T. et al., 2013. Review Assessment of Genetic Causes of Cardiac Arrest. Canadian Journal of 
Cardiology, vol. 29, pag. 100–110. 
13 Sinagra G; Mestroni L. ; Camerini F., 2012. Genetic Cardiomyopathies – a clinical approach. Springer 
ISBN 978-88-470-2756-5  
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1. GUIDELINES FOR AUTOPSY INVESTIGATION OF SUDDEN CARDIAC 
DEATH (SCD) AND INDICATIONS FOR MOLECULAR AUTOPSY 
 
The role of the autopsy in sudden death is most important to establish: 
1) Whether the death is attributable to a cardiac disease or to other causes of sudden death; 
2) The nature of the cardiac disease, and whether the mechanism was arrhythmic or 
mechanical;  
3) Whether the cardiac condition causing sudden death may be inherited, requiring screening 
and counselling of the next of kin; 
4) The possibility of toxic or illicit drug abuse and other unnatural deaths.14 
Any potential source of information should be interrogated, preferentially before autopsy 
is carried out. Ideally, the following information is required: 
- Age, gender, occupation, lifestyle 
- Circumstances of death (date, time interval, place of death)  
- Medical history; 
- Family cardiac history. 
All sudden death autopsies should be sequential structured examinations. They should 
specifically address the major causes of extra-cardiac sudden death. Principles and rules 
relating to autopsy procedures should adhere to the Recommendations on the 
Harmonisation of Medico Legal Autopsy Rules produced by the Committee of Ministers 
of the Council of Europe.15     
    
 
 
 
 
 
 
                                                             
 
15 Brinkmann B (1999) harmonization of medico legal autopsy rules. Committee of ministers. Council of 
Europe. Int J Legal Med 113:1-14 
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 External examination of the body 
- Establish body weight and height (to correlate with heart weight and wall thickness);16-17 
- Check for recent intravenous access, intubation, ECG pads, defibrillator and electrical 
burns, drain sites and traumatic lesions; 
- Check for implantable cardioverter defibrillator (ICD)/ pacemaker, if in situ, see MDA 
Safety Notice 2002 for safe removal and interrogation;18 
 Exclusion of non-cardiac causes of sudden death 
Any natural sudden death can be considered cardiac in origin after the exclusion of non 
cardiac causes. Thus, a full autopsy with sequential approach should be always performed 
to exclude common and un-common extra-cardiac causes of sudden death (cerebral; 
respiratory; acute haemorrhagic shock; septic shock). 
 Search for cardiac causes of sudden death 
- Many cardiovascular diseases can cause SCD, either through an arrhythmic mechanism 
(electrical SCD) or by compromising the mechanical function of the heart (mechanical 
SCD). These disorders may affect the coronary arteries, the myocardium, the cardiac 
valves, the conducting system, the intra-pericardial aorta or the pulmonary artery, the 
integrity of which is essential for a regular heart function. 
- The standard  gross examination of the heart; 
- The standard histologic examination of the heart Myocardium (in particular cases, 
Electron microscopy investigation; 
- Further laboratory tests: molecular or toxicologic studies. 
 Molecular Pathology 
Molecular studies of SCD include both detection of viral genomes in inflammatory 
cardiomyopathies, and gene mutational analysis in both structural and non-structural 
genetically determined heart diseases19. 
                                                             
16 Kitzman DW, Scholz DG, Hagen PT, et al. Age-related changes in normal human hearts during the first 
10 decades of life. Part II (maturity): a quantitative anatomic study of 765 specimens form subjects 20 to 
99 years old. Mayo Clin Proc 63:137-146.  
17 Schulz DM, Giordano DA (1962) hearts of infants and children: weights and measurements. Arch 
Pathol 73:464-471. 
18  
19   5. Chugh SS, Senashova O, Watts A, et al. Postmortem molecular screening in unexplained sudden 
death. J Am Coll Cardiol 2004;43:1625–1629. 
9 
 
For these purposes: 10 ml of EDTA blood and 5g of heart and spleen tissues are either 
frozen and stored at -80°C, or alternatively stored in RNA later at 4°C for up to e weeks. 
 Formulation of diagnosis  
The report should conclude with a clear clinicopathological summary. As far as possible 
this should relate the pathological findings to the clinical history, the circumstances of the 
death and any investigation performed close to the time of the death. In the majority of 
SCDs, a clear pathological cause can be identified, albeit with varying degrees of 
confidence. Wherever possible, the most likely underlying cause should be stated and the 
need for familial clinical screening and genetic analysis clearly indicated. It is important 
to accept that different degrees of certainty exist in defining the cause-effect relationship 
between the cardiovascular substrate and the sudden death event. Finally, there are 
myocardial diseases in which the border between physiological and pathological changes 
is poorly defined.  
Death that remain unexplained after careful macroscopic, microscopic and laboratory 
investigation should be classified as sudden arrhythmic death syndrome. There is 
increasing evidence that SCD in these instances might be due to inherited ion channel 
disorders, such as long QT and short QT syndromes, Brugada syndrome and 
catecholaminergic polymorphic ventricular tachycardia sick sinus sindrome, which 
present with well-defined abnormalities of basal ECG. In this setting, the availability of 
ECG tracing may be crucial for the diagnosis and molecular studies are essential. First 
degree relatives should undergo clinical screening and subsequent genetic analysis when 
indicated. 
New methods of preventing potentially fatal arrhythmias have been developed and the 
accurate diagnosis of SCD is now of particular importance. The guidelines represent the 
minimum standards of practice that should be adopted throughout the European Union 
and elsewhere. 
A careful cardiac investigation during the autopsy can provide a definitive diagnosis in 
structural heart diseases, be it by the identification of a culprit coronary lesion or heart 
muscle disease, which explain the episode. However, a significant number of SCD cases 
remain unexplained after a comprehensive medicolegal investigation. These autopsies are 
usually labeled as negative, natural, or arrhythmogenic. In these negative autopsies, 
10 
 
especially in the young, a genetic disease causing an electrical disturbance (ion 
channelopathy) should be immediately suspected. Because of the familial nature of the 
disease, the identification of these genetic defects carry important implications for 
relatives who are at potential risk of also having a fatal cardiac condition.20  
Key principles of postmortem investigations of sudden unexpected death in the young 
adapted from “Postmortem in sudden unexpected death in the young: guidelines on 
autopsy practice,” devised by TRAGADY - Trans-Tasman Response Against Sudden 
Death in the Young - and endorsed bythe Royal College of Pathologists of Australasia.21 
 
 
                                                             
20 O. Campuzano, P. Beltra´n-A´ lvarez, A. Iglesias, F. Scornik, G. Pe´rez, R. Brugada. Genetics and 
cardiac channelopathies. Genetics in medicine – Vol. 12, Number 5, May 2010. 
21Tragady. [Accessed June 18, 2012] Post-mortem in sudden unexpected death in the young: guidelines on 
autopsy practice Sydney: Royal College of Pathologists of Australasia. 2008. http:/ 
www.rcpa.edu.au/applications/DocumentLibraryManager2/upload/SUDYbestpracticedocumentendorsed
May2708%20(2).pdf.  
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2. ION CHANNEL DISEASES: GENETICS AND CARDIAC 
CHANNELOPATHIES. 
Inherited cardiac diseases associated with SCD can be classified into two broad groups: 
1. Primary electrical diseases, or channelopathies, in which the arrhythmogenic substrate 
is found in the electrical properties of the heart, and 
2. Cardiomyopathies, in which structural abnormalities such as hypertrophy, dilatation, 
or fatty and/or fibrotic infiltration, are responsible for inducing the arrhythmia. 
 
 
 
1. Cardiac conduction system cell. genes identified in human cardiac conduction system disease 
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2.1 Diseases of Automaticity 
Normal heart rhythm (sinus rhythm) depends on regular activity of the sinoatrial node 
(SAN), a heterogeneous collection of specialized myocytes in the right atrium. SAN cells, 
in general, possess a unique electrophysiological profile that promotes spontaneous 
electrical activity (automaticity).22 
Cells in the pacemaker and conduction system possess the defining characteristic of 
automaticity, an ability to generate an action potential in the absence of an external 
stimulus. Automaticity is required for cardiac pacemaking and depends on a unique ion 
channel expression profile conducive to spontaneous Action Potential generation.23 
The human sinoatrial node (SAN) is a crescent-shaped, intramural structure with its head 
located subepicardially at the junction of the right atrium and the superior vena cava and 
its tail extending 10 to 20 mm along the crista terminalis. The SAN has complex 3-
dimensional tissue architecture with central and peripheral components made up of 
distinct ion channel and gap junction expression profiles. Central and peripheral cells 
have different action potential characteristics and conduction properties (Figure 2). The 
central SAN, the site of dominant pacemaking, is electronically insulated from the 
hyperpolarizing atrial myocardium through the differential expression of connexins and 
ion channels. Peripheral SAN cells are electrophysiologically intermediate between 
central cells and atrial cardiomyocytes. 
  
                                                             
22 SathyaD.Unudurthi, RoseanneM.Wolf and ThomasJ.Hund. Role of sinoatrial node architecture in 
maintaining a balanced source-sink relationship and synchronous cardiac pacemaking. 
FrontiersinPhysiology | CardiacElectrophysiology November2014, Volume5, Article 446. 
23 Verkerk AO, Wilders R. Pacemaker activity of the human sinoatrial node: effects of HCN4mutations on 
the hyperpolarization-activated current. Europace. 2014 Mar;16(3):384-95. 
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Figure 2 Electrophysiological heterogeneity of the sinoatrial node (SAN) 
 
 
Human mutations affecting the voltage clock (SCN5A and HCN4), calcium clock (RYR2 
and CASQ2), or both mechanisms (ANKB) have been identified that negatively affect 
sinus node function.24 
Among the important currents contributing to diastolic depolarization is the 
hyperpolarization-activated “funny” current (If) (due primarily to HCN4 in SAN cells), 
with permeability to both Na+ and K+ and biophysical properties that make it a 
depolarizing current during diastole. If activates as the membrane potential approaches 
its max diastolic value and helps to spontaneously depolarize the membrane.25 At the 
same time, a low level of Ca2+ release from sarcoplasmic reticulum ryanodine receptor 
                                                             
24 David S. Park, MD, PhD; Glenn I. Fishman, MD. The Cardiac Conduction System. Circulation. 
2011;123:904-915. 
25  DiFrancesco D. The role of the funny current in pacemaker activity. Circ Res. 2010 Feb 
19;106(3):434-46. 
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Ca2+ release channels likely promotes a depolarizing current via the Na+/Ca2+ 
exchanger (Lakatta et al., 2010). 
 
2.2 HCN4 Diseases of Automaticity 
Hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels contribute to the 
pacemaker current (If) that is responsible for generating and regulating heart rhythm. 
Loss-of-function mutations of HCN4, the major HCN channel subunit in pacemaker cells, 
cause bradycardia. Moreover, cardiac tachyarrhythmias have also been shown to be 
associated with dysfunctional HCN4 channels.26 Although the pathogenic role of HCN 
channel mutations in cardiac tachyarrhythmias remains to be determined, one of the clues 
can be found in the suggested function of If in preventing bradycardia-induced ventricular 
arrhythmias by inhibiting early after-depolarization.27 
The pacemaker, or funny current, If, is generated by the hyperpolarization-activated 
cyclic nucleotide-gated (HCN) channel. The term funny current stems from the unique 
characteristics of HCN channels, which include permeability to K+ and Na+, activation 
at hyperpolarized membrane potentials, and modulation by cAMP. The biophysical 
properties of HCN channels make them ideally suited to function as modulators of the 
pacemaker potential.28 First, because they are activated at hyperpolarized membrane 
potentials (between_65 and _40 mV), their slow inward current contributes to diastolic 
depolarization; second, the main cardiac HCN channel (HCN4) is cAMP responsive, 
allowing If to be modulated by autonomic stimulation29. 
 
 
 
 
                                                             
26 Baruscotti M, Bottelli G, Milanesi R, DiFrancesco JC, DiFrancesco D. HCN-related channelopathies 
Pflugers Arch. 2010 Jul;460(2):405-15. 
27 Scicchitano P, Carbonara S, Ricci G, Mandurino C, Locorotondo M, Bulzis G, Gesualdo M, Zito A, 
Carbonara R, Dentamaro I, Riccioni G, Ciccone MM. HCN channels and heart rate. Molecules. 2012 Apr 
5;17(4):4225-35. 
28 Milano A, Vermeer AM, Lodder EM et al. HCN4 mutations in multiple families with bradycardia and 
left ventricular noncompaction cardiomyopathy. J Am Coll Cardiol. 2014 Aug 26;64(8):745-56. 
29 DiFrancesco D. funny channel gene mutations associated with arrhythmias. J Physiol. 2013 Sep 
1;591(Pt17):4117-24. 
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2.3 Sick sinus syndrome 
Sick sinus syndrome refers to a collection of disorders marked by the heart’s inability to 
perform its pacemaking function. Intrinsic causes include degenerative fibrosis, ion 
channel dysfunction, and remodeling of the sinoatrial node.30  
The hyperpolarization-activated ‘funny’ current, If, plays an important modulating role 
in the pacemaker activity of the human sinoatrial node (SAN). If is carried by 
hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, which are tetramers 
built of four HCN subunits. In human SAN, HCN4 is the most abundant of the four 
isoforms of the HCN family (Figure 3). Since 2003, several loss-of-function mutations in 
the HCN4 gene, which encodes the HCN4 protein, or in the KCNE2 gene, which encodes 
the MiRP1 accessory b-subunit, have been associated with sinus node dysfunction.31 
The SAN dysfunction is characterized by an atrial rate that is inappropriate for 
physiological requirements and presents itself with a combination of symptoms such as 
dizziness, fatigue, and syncope.32 
 
                                                             
30 Duhme N, Schweizer PA, Thomas D, et al. Altered HCN4 channel C-linker interaction is associated with 
familial tachycardia-bradycardia syndrome and atrial fibrillation. Eur Heart J. 2013 Sep;34(35):2768-75. 
Epub 2012 Nov 23. 
31 Arie O. Verkerk and RonaldWilders. Pacemaker activity of the human sinoatrial node: effects of HCN4 
mutations on the hyperpolarization-activated current. European Society of Cardiology (2014) 16, 384–395. 
32 Dobrzynski H, Boyett MR, Anderson RH. Newinsights into pacemaker activity: promoting 
understanding of sick sinus syndrome. Circulation 2007;115:1921–32. 
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Figure 3 Mutations in HCN4 and MiRP1 associated with sinus bradycardia 
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3. DISEASES ASSOCIATED WITH SODIUM CHANNEL DYSFUNCTION 
The α-subunit of the cardiac isoform of the sodium channel is known as Nav1.5 and is 
encoded by the SCN5A gene. Nav1.5 is a membrane protein that contains 2015 or 2016 
residues (depending on the splice variant) for an approximate molecular weight of 227 
kDa. It consists of four homologous domains, known as DI to DIV, joined by so-called 
linkers.33 These three linkers in addition to the N-terminus and the C-terminus of the 
protein are cytoplasmic. Each domain, DI to DIV, contains six transmembrane helices 
(namely S1–S6) linked by intracellular or extracellular loops. S5 and S6 in each of the 
domains form the pore-lining helices, and the extracellular loop between them is the 
longest among extracellular segments of Nav1.5.34 
 
 
 
 
 
Malfunctioning of cardiac Na+ channels is the cause of some primary arrhythmia 
syndromes.35 Among others, four diseases have been associated to genetic mutations that 
affect Na+ channel function: Brugada syndrome (BrS), Lev-Lene`gre syndrome (familial 
                                                             
33 Bennett PB, Yazawa K, Makita N, George AL Jr. Molecular mechanism for an inherited cardiac 
arrhythmia. Nature 1995;376:683– 685. 
34 9. Benson DW, Wang DW, Dyment M, et al. Congenital sick sinus syndrome caused by recessive 
mutations in the cardiac sodium channel gene (SCN5A). J Clin Invest 2003;112:1019 –1028. 
35 Tan HL, Bink-Boelkens MT, Bezzina CR, et al. A sodium-channel mutation causes isolated cardiac 
conduction disease. Nature 2001;409:1043–1047. 
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progressive conduction disease), long QT syndrome (LQTS), and familial atrial 
fibrillation (AF). Certain mutations can give rise to different phenotypes with enhanced 
or reduced channel function and even combinations of phenotypes. 
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3.1 Brugada syndrome 
Brugada syndrome (BrS) was described 20 years ago as a new clinical entity characterized 
by the presence of a typical electrocardiographic (ECG) pattern (right bundle branch 
block and persistent ST -segment elevation in right precordial leads) and associated with 
a high risk of sudden cardiac death (SCD)36. 
Currently, it is believed to be responsible for 12% of SCD cases and 20% of SCD in 
patients with structurally normal hearts. Patients may suffer syncope or SCD secondary 
to polymorphic ventricular tachycardia (PVT )/ventricular fibrillation (VF ). However, 
the majority of patients remain completely asymptomatic. Some of the arrhythmias may 
occur after large meals, during rest, or while sleeping, believed to be due to high vagal 
tone. The symptoms usually appear around 40 years of age; however, there are reports of 
patients affected from ages 1 to 84.37 Males are more often symptomatic than females, 
probably from the influence of hormones and gender distribution of ion channels across 
the heart.38 
There is little information regarding the pediatric population, but studies performed in 
children have failed to identify a male predominance, perhaps due to low levels of 
testosterone in children of both genders.39 The prevalence of the disease is difficult to 
estimate because the pattern is not always recognized or because it may transiently 
normalize. Nevertheless, global prevalence varies from 5 to 20 in every 10,000, and it is 
considered endemic in Southeast Asian countries, where the prevalence is higher.40 
Molecular Mechanism - the characteristic right precordial ST -segment elevation in the 
ECG is not well understood. Currently there are two mechanisms that may explain the 
ECG alteration; neither mechanism has been conclusively confirmed, nor are they 
                                                             
36 Gussak I, Brugada P, Brugada J, et al. Idiopathic short QT interval: a new clinical syndrome? Cardiology 
2000;94:99 –102. 
37 Sheikh AS, Ranjan K. Brugada syndrome: a review of the literature. Clin Med. 2014 Oct;14(5):482-9. 
doi: 10.7861/clinmedicine.14-5-482. 
38 8. Grant AO, Carboni MP, Neplioueva V, et al. Long QT syndrome, Brugada syndrome, and conduction 
system disease are linked to a single sodium channel mutation. J Clin Invest 2002;110:1201–1209. 
39 Brugada R, Campuzano O, Sarquella-Brugada G, Brugada J,Brugada P. Brugada syndrome. Methodist 
Debakey Cardiovasc J. 2014 Jan-Mar;10(1):25-8. 
40 R. Brugada, O. Campuzano, G. Sarquella-Brugada, J. Brugada, P. Brugada. Brugada syndrome. 
houstonmethodist.org/debakey-journal. MDCVJ | X (1) 2014.  
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mutually exclusive.41 The first hypothesis, repolarization, focuses on the presence of 
transmural voltage gradients due to heterogeneity in action potential duration between the 
RV epicardium and endocardium (disequilibrium between INa and Ito). This generates 
transmural dispersion of repolarization and causes the ST-segment elevation.42 
The second hypothesis, depolarization, involves preferential conduction slowing in the 
RV outflow tract, leading to ST-segment elevation in the right precordial leads. Regional 
differences in conduction velocity in the RV epicardium would be aggravated by INa 
reduction and trigger the occurrence of epicardial reentrant excitation waves. 
Additionally, in 2009, Boukens et al. suggested that the embryological development of 
the right ventricle could explain the electrophysiological heterogeneity in the ventricular 
myocardium, including the RV outflow tract, which could provide the arrhythmogenic 
substrate.43 
Genetics - Brugada syndrome is a disease with an autosomal dominant pattern of 
transmission. Incomplete penetrance is frequent in families, and the disease can be 
sporadic in up to 60% of patients. In 1998, the first pathogenic mutation in the SCN5A 
gene was identified. This gene encodes the alpha subunit of the cardiac sodium channel 
(Nav1.5). Since then, more than 350 pathogenic mutations in several genes have been 
published (Table 1).44 
                                                             
41 Mashar M, Kwok AJ, Pinder R, Sabir I. The Brugada syndrome revisited. Trends Cardiovasc Med. 
2014 Jul;24(5):191-6. doi: 10.1016/j.tcm.2013.11.001. Epub 2013 Nov 11. 
42 Brugada P, Brugada J, Roy D. Brugada syndrome 1992-2012: 20 years of scientific excitement, and 
more. Eur Heart J. 2013 Dec;34(47):3610-5. doi: 10.1093/eurheartj/eht113. Epub 2013 Nov 1. 
43 Arbelo E, Brugada J. Risk stratification and treatment of brugada syndrome. Curr Cardiol Rep. 2014 
Jul;16(7):508. doi: 10.1007/s11886-014-0508-1.  
44  Barajas-Martínez H, Hu D, Antzelevitch C. Genetic and molecular basis for sodium channel-mediated 
Brugada syndrome. Arch Cardiol Mex. 2013 Oct-Dec;83(4):295-302. doi: 10.1016/j.acmx.2013.10.001. 
Epub 2013 Nov 21. 
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These genes encode subunits of cardiac sodium, potassium, and calcium channels as well 
as genes involved in the trafficking or regulation of these channels. Despite the high 
number of gene mutations, only about 35% of BrS patients have been determined to have 
a genetic cause. Of them, nearly 30% carry a pathogenic mutation in the SCN5A gene.45 
All other genes together are responsible for about 5% of all BrS cases. Therefore, 65% of 
cases do not have a genetic origin. 
Several factors could explain the high number of BrS patients without genetic alteration 
after genetic screening. For example, copy number variations have already been reported 
in SCN5A. In addition, pathogenic mutations associated with BrS could be localized in 
unknown genes, or the disease could be related to epigenetic factors, mainly DNA 
methylation, post-translational modifications, and RNA mechanisms. All these factors 
                                                             
45 Liu M, Yang KC, Dudley SC Jr. Cardiac sodium channel mutations: why so many phenotypes? Nat Rev 
Cardiol. 2014 Oct;11(10):607-15. doi: 10.1038/nrcardio.2014.85. Epub 2014 Jun 24.  
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could also explain, at least in part, incomplete penetrance and variable expressivity 
characteristics in BrS families.46 
Risk stratification - It is well accepted that the etiology of BrS is multifactorial, involving 
genetic, environmental, and hormonal components that contribute to its phenotype 
manifestation. In addition, some clinical features have been identified as high-risk 
markers in BrS. It is established that symptomatic patients with recurrent syncope, agonal 
respiration during sleep, or unknown seizures are at risk of sudden death and need ICD. 
However, a debate is still ongoing on the value of risk stratification parameters, such as 
electrophysiological inducibility, in asymptomatic patients. Some will argue that it has 
no value, while others will claim that the electrophysiology study (EPS ) enables the 
identification of a subgroup of asymptomatic patients at higher risk who will benefit from 
ICD implantation. 
Other modulating factors also have been investigated. For example, genetic studies have 
reported that compound pathogenic mutations in BrS patients cause more severe 
phenotype and that common polymorphisms may modulate the effect caused by 
pathogenic mutations. In addition, it recently has been published that pathogenic 
mutations in combination with common single nucleotide polymorphisms could increase 
the risk of arrhythmias in BrS patients, though at present genetics are not useful in risk 
stratification. At this time, genetic screening is only recommended as a diagnostic tool.47 
 
 
 
 
 
 
 
 
 
                                                             
46  Miller D, Wang L, Zhong J. Sodium channels, cardiac arrhythmia, and therapeutic strategy. 
Adv Pharmacol. 2014;70:367-92. doi: 10.1016/B978-0-12-417197-8.00012-2.Review. 
47 R. Brugada, O. Campuzano, G. Sarquella-Brugada, J. Brugada, P. Brugada. Brugada syndrome. 
houstonmethodist.org/debakey-journal. MDCVJ | X (1) 2014. 
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3.2  Lev-Lenegre syndrome 
Lev-Lenegre syndrome is a progressive cardiac conduction disease characterized by 
gradually developed ventricular fibrosis of the conduction system, which may lead to 
arrhythmias or asystolia. The first locus for the disease was reported in 1995, on 
chromosome 19q13.2–13.3.48 In 1999, the first mutations causing the disease were 
associated with SCN5A.24 Mutations in SCN5A lead to a reduction in Na+ current, 
reducing the velocity of the impulse conduction.11 
Electrocardiographically, both Lenegre and Lev disease are characterized by chronic 
conduction delay through the His-Purkinje system, resulting in partial or complete AV-
block and right or left bundle branch block.49 In both diseases a sclerodegenerative 
process causes fibrosis of the His-Purkinje fibres. The severity and extent of the fibrosis 
in these diseases, however, is different. In Lenegre disease, a diffuse fibrotic degeneration 
is limited to the conduction fibres, while in Lev disease the sclerodegenerative 
abnormalities affect both the specialized conduction system and the fibrous skeleton of 
the heart. An inherited component may be involved in both diseases. However, 
particularly Lev disease may be a variation of the normal ageing process.50 
 
 
 
 
 
 
 
 
 
 
 
                                                             
48 Brink PA, Ferreira A, Moolman JC, Weymar HW, van der Merwe PL, Corfield VA. Gene for progressive 
familial heart block type I maps to chromosome 19q13. Circulation 1995;91:1633–1640. 
49 Lev M, Cuadros H, Milton HP. Interruption of the atrioventricular bundle with congenital 
atrioventricular block. Circulation 1971;43:703e10. 
50 Harrison’s principles of internal medicine, online edition, http://harrisons.accessmedicine.com 
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3.3  Long QT Syndrome 
The prevalence of congenital LQTS is reported to be approximately 1/2,000. Syncope is 
generally the most commonly encountered first episode in LQTS patients, and aborted 
cardiac arrest/sudden cardiac death (ACA/SCD) is rare (1–3%). 
Of the patients who eventually become symptomatic, 50% experience their first cardiac 
event by the age of 12, and 90% by the age of 40. LQTS is also known as an etiology of 
sudden infant death syndrome (SIDS) and in approximately 10% of SIDS cases the infant 
carried a mutation in a LQTS-causing gene.51 
The most frequent LQTS subtypes are type 1 (LQT1), type 2 (LQT2) and type 3 (LQT3). 
The subdivision is based on the underlying genetic substrate, with the potassium channel 
genes, KCNQ1, KCNH2, and the sodium channel gene, SCN5A, as the involved genes. 
Specific triggers of symptoms are known in these major LQTS subtypes.52 For example 
in LQT1, cardiac events occur during physical exertion or emotional stress, typically 
during swimming, whereas auditory stimulation such as an alarm clock or a telephone 
bell is a typical trigger for arrhythmic events in LQT2.53 Emotional stress, as well as the 
postpartum period, are also frequently observed triggers of arrhythmia in LQT2. More 
recently, a history of epilepsy has been reported to be more common with LQT2 (39%) 
than with other subtypes of LQTS (10%, P<0.001), possibly because KCNH2 is 
expressed in the brain as well. Obviously in such cases, the differential diagnosis of LQTS 
and epilepsy is important for treatment, because LQTS is often mistreated as epilepsy 
because of generalized seizures secondary to torsades de pointes. In LQT3, symptoms are 
most frequently observed during rest or at night.54 
Diagnosis - shows the LQTS diagnostic scoring system (updated in 2011), which includes 
symptoms, family history and ECG findings.16 Patients with a Schwartz score ≥3.5 
points in the absence of a secondary cause for QT prolongation are diagnosed as LQTS. 
                                                             
51 Benito B, Brugada R, Perich RM, et al. A mutation in the sodium channel is responsible for the 
association of long QT syndrome and familial atrial fibrillation. Heart Rhythm 2008;5:1434 –1440. 
52 Barsheshet A, Dotsenko O, Goldenberg I. Congenital long QT syndromes: prevalence, pathophysiology 
and management. Paediatr Drugs. 2014 Dec;16(6):447-56. 
53 Adler A, Uppal S, Orr N, Alzoughool F, Gollob MH. First report of a large duplication of the KCNQ1 
gene in a patient with long QT syndrome. Can J Cardiol. 2014 Oct;30(10):1249.e5-7. 
54 Campuzano O, Sarquella-Brugada G, Mademont-Soler I, et al. Identification of Genetic Alterations, as 
Causative GeneticDefects in Long QT Syndrome, Using Next Generation Sequencing Technology. PLoS 
One. 2014 Dec 10;9(12):e114894. 
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Typical LQTS cases can be readily diagnosed with this scoring system, whereas latent 
LQTS patients with normal QTc at rest, found in 36% of LQT1, 19% of LQT2 and 10% 
of LQT3, respectively, may show a non-diagnostic score of 1–3 points. In such cases, 
serial ECGs, 24-h Holter recordings, and an exercise or epinephrine test are recommended 
to reveal subclinical QT prolongation.55 
 
 
3 LQTS Diagnostic criteria                  
 
The QT interval reflects repolarization of the ventricular action potentials orchestrated by 
various cardiac ion currents, including sodium, calcium and potassium currents. When a 
decreased potassium current (loss-of-function) or increased sodium or calcium current 
(gain-of-function) is caused by a mutation in an ion channel or axillary protein, a 
                                                             
55  Tester DJ, Ackerman MJ. Genetics of long QT syndrome. Methodist Debakey Cardiovasc J. 2014 Jan-
Mar;10(1):29-33. 
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prolongation of the action potential duration occurs, which manifests on the 12-lead ECG 
as QT prolongation.56 
In 1995 and 1996, causal gene mutations of familial LQTS in 3 genes (KCNQ1, KCNH2 
and SCN5A) were discovered. To date, mutations in 15 different genes have been 
reported in LQTS, but KCNQ1, KCNH2 and SCN5A remain numerically the major genes 
in LQTS and comprise more than 90% of genotype-positive cases of LQTS. 
 
Figure 5. congenital LQTS genes and affected Ion Current 
 
A causal mutation is found in approximately 75% of LQTS patients with a Schwartz score 
≥4,42 but the genetic background of the other 25% of patients remain elusive. 
In approximately 85% of genotype-positive cases of LQTS, the patient carries a mutation 
inherited from one of the parents and in the remaining 15% a de novo mutation is 
pertinent. In genotyped LQTS patients, approximately 50% have no lifetime symptoms, 
and 10–50% of such patients show no apparent QT prolongation. Compound mutations 
                                                             
56 Harmer SC, Mohal JS, Royal AA, McKenna WJ, Lambiase PD, Tinker A. Cellular mechanisms 
underlying the increased disease severity seen for patients with long QT syndrome caused by compound 
mutations in KCNQ1. Biochem J. 2014 Aug 15;462(1):133-42  
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(ie, ≥2 mutations) are found in 10% of genotype-positive patients47 and the clinical 
manifestation of disease in such patients is often more severe. 
As for minor LQTS subtypes with severe clinical phenotypes, mutations in KCNQ1 or 
KCNE1 present as homozygous or compound heterozygous mutations in Jervell and 
Lange-Nielsen syndrome. KCNQ1 mutations are much more prevalent (90%) than 
KCNE1 mutations (10%). Calmodulin de novo mutations were reported in infant cases 
of recurrent cardiac arrest by means of exome sequencing in the parents-child trio. 
Since the beginning of research into the genetic background in LQTS, linkage analysis 
and the candidate gene approach have been used, assuming LQTS to be a monogenic 
model. Later, it became evident from research into large LQTS families that LQTS 
actually shows incomplete penetrance with variable expressivity. In other words, different 
clinical phenotypes (sudden death, syncope, asymptomatic) are observed in family 
members carrying the same familial mutation, which may be caused by a more complex 
genetic model involving multiple genetic and environmental factors affecting disease 
development. 57  
Modifier genes are common genetic variants found in more than 1% of affected 
individuals, which have an influence on susceptibility to disease. They have less effect 
on disease compared with a causal gene mutation, but by summing up the effects of such 
modifier genes, the disease severity varies. In LQTS, variants in the coding regions of 
LQTS-related genes such as KCNE1 D85N, KCNH2 K897T, and SCN5A H558R are 
known to influence the QT interval. Single nucleotide polymorphisms (SNPs) in non-
coding regions (intron, 3’UTR) of KCNQ1 are also reported as an important QT-interval 
modifier. Furthermore, genome-wide association studies have revealed SNPs in NOS1AP 
as a modulator of QT interval in LQTS patients, as well as in the general population. An 
effort to find any SNPs affecting QT interval of the Caucasian general population 
continues by larger international consortia. This field is expected to expand to further 
understand the complexity of genotype-phenotype relationship in LQTS. However, it 
remains currently at the research level, which requires careful interpretation by experts. 
                                                             
57 Kolder IC, Tanck MW, Postema PG, et al. Analysis for Genetic Modifiers of Disease Severity in Patients 
with Long QT Syndrome Type 2. Circ Cardiovasc Genet. 2015 Mar 3. 
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Beta-blocker therapy is the first choice for LQTS. It dramatically decreases event rates, 
from 0.97 to 0.31 events per patient per year. Recurrent events were often seen in patients 
with a history of ACA or in patients who are non-compliant with β-blocker therapy. In 
LQT1 and LQT2, propranolol (2–4 mg · kg–1 · day–1) and nadolol (1–1.5 mg · kg–1 · 
day–1) have been shown to be much more effective than metoprolol in suppressing 
recurrent cardiac events. Therefore, metoprolol should probably not be prescribed in 
symptomatic LQTS patients. Atenolol, not included in the aforementioned study, appears 
to be less effective, according to a study performed in (only) 28 genotyped patients with 
a median follow-up of 46 months. 
LCSD is a surgical procedure to ablate the lower two-thirds of the left stellate ganglion 
together with the thoracic ganglia T2–T4 to denervate cardiac sympathetic innervation to 
the heart. It is currently used as an adjunctive therapy in symptomatic patients who are 
refractory to β-blocker therapy. LCSD has been shown to reduce cardiac events 
significantly in LQTS with a rather high long-term cardiac-event-free survival (46%/5 
years,91 59%/2 years). In patients with a history of syncope, post-LCSD QTc <500 ms 
predicts efficacy of LCSD. 
However, those with persistent QTc prolongation (≥500 ms) have a high chance of SCD 
and need to be protected with an ICD. A known complication of this procedure is 
Horner’s syndrome, but in most cases, it is only transiently observed after the surgery and 
the patient recovers afterwards. 
Use of an ICD should be regarded as adjunctive therapy in LQTS. An ICD is 
recommended only for patients who have frequent syncopal episodes despite being on 
maximal doses of β-blocker (and eventually other additional pharmacological therapies) 
or at high risk of recurrent ACA/SCD, such as patients who have a history of ACA, 
symptomatic infant cases (<1 year of age) or those with J-LNS. 
In LQTS genetics, next-generation sequencing enables us to detect SNPs in coding/non-
coding regions of (LQTS-related) genes that modify the QT interval. Currently, analysis 
and interpretation of results by next-generation sequencing remains at the research level 
while advances in the understanding of genotype-phenotype relationships, including 
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LQTS causal genes as well as SNPs, are expected to guide us further to genetically-guided 
personalized treatment in the future.58 
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4. DISEASES ASSOCIATED WITH POTASSIUM CHANNEL DYSFUNCTION 
The potassium channels most relevant to heart diseases are the slowly activating delayed 
rectifier cardiac K+ channel and the voltage-gated inwardly rectifying K+ channel. The   
α-subunits of the cardiac isoforms of these two potassium channels are known as 
KvLQT1 and KCNH2, respectively. Potassium channels allow repolarization currents to 
counteract the preceding depolarization process.59 Mutations in the genes that encode the 
K+ channels may give rise to three types of disease: LQTS, short QT syndrome (SQTS), 
and Atrial Fibrillation.60 
Loss-of-function mutations of potassium channel genes (KCNQ1, KCNH2, KCNE1, 
KCNE2, KCNJ2, and KCNJ5) in LQTS reduce the repolarizing currents (IKr, IKs, and 
IKir) required to terminate the cardiac action potential, leading to a prolongation of the 
QT interval. Gain-of-function mutations in calcium channel (CACNA1C) and sodium 
channel genes (SCN5A and SCN4B) in LQTS cause delayed channel closing and 
inactivation, responsible for prolonged inward currents and depolarization with a 
resultant increased QT interval. By contrast, loss-of-function mutations in calcium 
channel genes (CACNA1C, CACNB2, and CACNA2D1) and gain-of-function mutations 
in potassium channel genes (KCNH2, KCNQ1, and KCNJ2) enhance repolarization, 
resulting in the abnormal shortening of the cardiac action potential in short QT syndrome. 
Loss-of-function mutations in sodium channel genes have been identified to cause 
Brugada syndrome, familia atrial fibrillation, sick sinus syndrome, familial heart block, 
and atrial standstill. It is noteworthy that both gain-of-function mutations (which decrease 
action potential duration) and loss-of-function mutations (which increase action potential 
duration) in potassium channel genes predispose to atrial fibrillation. This demonstrates 
a precise atrial electrophysiological balance in which minor disturbances in either 
direction can cause atrial fibrillation.61  
 
 
                                                             
59 Ravens U, Cerbai E. Role of potassium currents in cardiac arrhythmias. Europace 2008;10:1133–1137. 
60 Jing L, Brownson K, Patwardhan A. Role of slow delayed rectifying potassium current in dynamics of 
repolarization and electrical memory in swine ventricles. J Physiol Sci. 2014 May;64(3):185-93. 
61 Schmitt N, Grunnet M, Olesen SP. Cardiac potassium channel subtypes: new roles in repolarization and 
arrhythmia. Physiol Rev. 2014 Apr;94(2):609-53. 
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4.1 Atrial fibrillation 
AF is the most common arrhythmia observed in clinical practice. Several loci have been 
mapped and most of them encode for subunits of potassium channels.  
Identification of KCNQ1 as responsible for the disease provided the first link of the 
genetic for of the arrhythmia with an ion channelopathy.62 
A gain of function in Iks current when the mutated channel was expressed  explained well 
the shortening of the action potential duration and effective refractory period, which are 
thought to be the culprits of the disease.63 
Defects in genes encoding for potassium currents were further confirmed responsible for 
AF with the identification of gain of function mutations in KCNE2, in KCNH2 (causing 
AF and short-QT-syndrome) and in Kir2.1.64 A genetic defect has been described in 
KCNE3; however, the functional analysis did not demonstrate a different biophysical 
effect caused by the mutant genetic defect, indicating that it could be a rare 
polymorphism.65 In summary, the biophysical findings therefore indicated a role of gain-
of-function mutations in potassium channels in AF highlighting the pathophysiological 
role of shortened atrial action potentials.66 When Olson et al. described a loss of function 
mutation in KCNA5, the gene that encodes Kv1.5, the debate became more stimulating 
because it initiated the hypothesis that a prolongation of the action potential can also be 
a basic mechanism for development of AF.67 
 
 
 
 
                                                             
62  Zhao J, Liu T, Li G. Relationship between two arrhythmias: sinus node dysfunction and atrial fibrillation. 
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32 
 
5. DISEASES ASSOCIATED WITH CALCIUM CHANNEL DYSFUNCTION 
The voltage-gated calcium channel subunit alpha, Cav1.2, encoded by CACNA1C,  
It is a membrane protein with a similar topology to the subunit of the sodium channel: it 
consists of four homologous domains (DI to DIV), joined by cytosolic linkers. Each 
domain also contains six transmembrane helices. On the other hand, the Ryanodine 
receptor 2, encoded by RyR2, and the calsequestrin 2, encoded by the RyR2 and CASQ2, 
respectively, locate at the sarcoplasmic reticulum.  
Calcium ions are involved in phase 2 of cardiac action potential and also increase the 
output of calcium from the sarcoplasmic reticulum, which functions primarily as a 
storehouse of calcium in the skeletal muscle, to trigger cardiac contraction. The role of 
calcium channels in inherited arrhythmia syndromes has only recently been 
demonstrated. To date, a Ca2_ channel dysfunction can produce three different 
diseases—a combination of BrS with shorter than normal QT interval, Timothy syndrome 
(TS), and Polymorphic Ventricular Tachycardia. 
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5.1 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is characterized by 
the development of bidirectional polymorphic ventricular tachycardia upon exposure to 
adrenergic stimulation in an otherwise normal heart. Experiencing emotional or physical 
stress can induce dizziness, syncope, and/or sudden cardiac death in patients with 
CPVT.68 Manifestations occur in childhood or adolescence, with the average onset at age 
7-9 years49). CPVT can be inherited in an autosomal-dominant or recessive manner. The 
autosomal-dominant form of CPVT (CPVT type 1) is caused by gain-of-function 
mutations in RYR2, the gene that encodes the cardiac ryanodine receptor 2 (RYR2), a 
major component of RYR2 channels.69 RYR2 channels mediate calcium release from the 
SR into the cytosol upon cell membrane depolarization. Defective closure of RYR2 
channels results in intracellular calcium leakage from the SR, which leads to increased 
potential for delayed after-depolarizations and subsequent ventricular tachycardia50).70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                             
68 Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie 
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6. MOLECULAR GENETIC RESULTS  
Were examined for a cardiac channel diseases, 9 cases of SUD (Sudden Unexplained 
Death) occurring in the Institute of legal medicine of Palermo, and 3 cases of clinical 
arrhythmias diseases occurring in the department of Clinical Cardiology in Palermo 
Hospital.  
Of these, 12 (10 male and 2 female). Polymerase chain reaction, and DNA sequencing  
were used for a comprehensive mutational analysis of the 3 major channelopathy 
susceptibility genes (SCN5A, KCNQ1 and HCN4) and in one clinical case a targeted 
analysis of the arrhythmogenic right ventricular dysplasia/cardimiopathy associated 
(ARVD/C)-, DSP-encoded cardiac desmosome junctions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sudden Unexplained Death 
 Case Gender Age Molecular 
Autopsy 
Dna 
source 
Mutation 
analysis 
technique 
1 54.09 M 35 HCN4 formalin-fixed 
paraffin embedded 
tissue 
(FF-PET) 
PCR 
DNA 
sequencing 
2 88.09 M 44 HCN4 formalin-fixed 
paraffin embedded 
tissue 
(FF-PET) 
PCR 
DNA 
sequencing 
3 67.11 F 19 HCN4 formalin-fixed 
paraffin embedded 
tissue 
(FF-PET) 
PCR 
DNA 
sequencing 
4 10.12 M 25 HCN4 formalin-fixed 
paraffin embedded 
tissue 
(FF-PET) 
PCR 
DNA 
sequencing 
5 11.12 M 25 HCN4 formalin-fixed 
paraffin embedded 
tissue 
(FF-PET) 
 
PCR 
DNA 
sequencing 
6 15.12 F 25 HCN4 formalin-fixed 
paraffin embedded 
tissue (FF-PET) 
PCR 
DNA 
sequencing 
7 S01 M 20 SCN5A 
KCNQ1 
HCN4 
Autopsy blood PCR 
DNA 
sequencing 
8 S02 M 25 SCN5A 
KCNQ1 
HCN4 
 
Autopsy blood PCR 
DNA 
sequencing 
9 S03 M 17 SCN5A Autopsy blood PCR 
DNA 
sequencing 
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Arrhythmogenic Cardiac Syndrome   
Case Gender Age Arrhythmogenic 
Diseases 
Genetic 
Screen 
Dna 
source 
method 
C01.13 M 25 ECG alterations 
ICD 
(Implantable Cardioverter 
Defibrillator) 
SCN5A 
KCNQ1 
HCN4 
 
Fresh 
Blood in 
EDTA 
PCR 
DNA 
sequencing 
C02.13 M 17 ECG alterations 
ICD 
(Implantable Cardioverter 
Defibrillator) 
SCN5A 
KCNQ1 
HCN4 
 
Fresh 
Blood in 
EDTA 
PCR 
DNA 
sequencing 
C03.13 M 21 Signs of Right ventricular 
failure 
No ECG alteration 
DSP Fresh 
Blood in 
EDTA 
PCR 
DNA 
sequencing 
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Genetic analysis of the HCN4 gene (exon 8) revealed the identical mutation (inserction) 
in 3 cases of autopsy-negative SUD; this mutation is unknown in Literature and probably 
is implicated in the susceptibility of action potential, generated by seno-atrial node, and 
cause of death may be due to lethal arrhythmias.  
 
Gene: 
HCN4 
Case Chr Position  Variant 
ID 
Variant 
Type 
Molecular  
conseguence 
Clinical 
Conseguence 
Ex 8e 15.12 
(C12) 
Chr 15 
73.323.339_38insA 
 
Unknown Insertion  susceptibility of 
SUD? 
Sudden Death 
Ex 8e 54.09 
(G02) 
Chr 15 
73.323.339_38insA 
 
Unknown Insertion  susceptibility of 
SUD? 
Sudden Death 
Ex 8e 67.11 
(H1) 
Chr 15 
73.323.339_38insA 
 
Unknown Insertion susceptibility of 
SUD? 
Sudden Death 
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HCN4 Ex8 Chr 15  
Case 15.12 (C12) 
HCN4 Ex8 Chr 15 
Case 54.09 (G02) 
HCN4 Ex8 Chr 15 
Case 67.11 (H1) 
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In the exon 8, we found other single nucleotide variant with heterozygous polymorphism   
 
Gene: 
HCN4 
Case Chr Position  Variant ID Variant Type Molecular  
conseguence 
 
Ex 8e 10.12 
(B07)  
Chr 15 
73.323.336 A>C 
p. Ser=Ser 
Unknown Heterozygous 
polymorphism  
Missense 
Ex 8e 15.12 
(C12) 
Chr 15 
73.323.336 A>C 
p. Ser=Ser 
Unknown Heterozygous 
polymorphism   
Missense 
Ex 8e 54.09 
(G02) 
Chr 15 
73.323.292 G>A 
rs 369485237 Single 
Nucleotide 
Variant 
Missense 
Ex 8e 67.11 
(H1) 
Chr 15 
73.323.292 G>A 
rs 369485237 Single 
Nucleotide 
Variant 
Missense 
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Another interesting results after genetic analysis of the HCN4 gene (intron 7) revealed 
the identical mutation in 3 cases (2 autopsy-negative SUD and 1 clinic arrhythmias treated 
with implantable cardioverter defibrillator); this mutation is known in Literature and your 
position is most important because involved a intron sequence, between exon 7 and exon 
8, and probably this intron variant region can play an important role in generation of two 
different spliced mRNA and/or the insertion of a stop codon. This mutation is probably 
involved in susceptibility of action potential, generated by seno-atrial node, and to 
produce a pathogenic and lethal arrhythmias. In the future the Splicing analysis are 
important for the classification of this polimorfisms as pathogenic variant.    
 
 
 
 
 
 
 
 
 
Gene: 
HCN4 
Case Chr Position 
Intron 7a 15.12 Chr 15 
73.324.294G>A 
Intron 7a 54.09 Chr 15 
73.324.294G>A 
Intron 7a C02.13 Chr 15 
73.324.294G>A 
Case Variant ID Molecular 
conseguence 
Worst 
Clinical 
significance  
Clinical 
Conseguence 
15.12 
(C08) 
rs481579 
Single nucleotide 
variant 
Intron variant 
 
Unknown Sudden Death 
54.09 
(F09) 
rs481579 
Single nucleotide 
variant 
Intron variant Unknown Sudden Death 
C02.13 
(H5) 
rs481579 
Single nucleotide 
variant 
Intron variant  Unknown Pathogenic arrhythmias 
treated with 
ICD implantable 
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HCN4 Int. 7a 
Case 15.12 (C08) 
HCN4 Int. 7a 
Case 54.09 (F09) 
HCN4 Int. 7a 
Case C02.13 (H5) 
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In HCN4-gene screen we found other heterozygous polymorphism unkwoun. 
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7. CONCLUSION  
More than one-fourth of autopsy-negative SUD cases may stem from channelopathic 
mutations. A cardiac channel molecular autopsy should be considered as a standard part 
of the evaluation of autopsy-negative SUD, especially among subjects with exercise-
induced SUD, and those with a positive personal or family history of cardiac events. 
The evaluation of SUD should be an interdisciplinary collaboration between an expert 
pathologist/medical examiner/coroner, cardiologist, and colleagues equipped with 
expertise in molecular genetic counseling. 
 
 
4 Multidisciplinary approach to the evaluation of sudden unexplained death (SUD). Herzschrittmacherther 
Elektrophysiol. 2012 September ; 23(3). 
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All families in which a sudden unexplained death has occurred require targeted and 
standardized clinical testing in an attempt to identify relatives who may be at-risk of 
having the same inherited heart disease and therefore also predisposed to an increased 
risk of SCD. 
Our results we propose future challenges consist in: the study of genotype/phenotype 
correlations, the phenotype interpretation of all these variants for its clinical translation; 
the routinely implementation of molecular autopsy in cases of autopsy-negative, and at 
the same time the genetic study of family members, in addition to clinical cases of 
arrhythmogenic cardiomyopathy, to prevent other cases of SUD.  
Next Generation Sequencing technology can be used efficiently to analyse the rest of the 
genes associated with the arrhythmogenic disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 
 
Abstract                                                                                                                                         Pag.3                                           
Introduction                                                                                                                                   Pag.4                                           
 
1. GUIDELINES FOR AUTOPSY INVESTIGATION OF SUDDEN CARDIAC DEATH 
(SCD) AND INDICATIONS FOR MOLECULAR AUTOPSY                                Pag.7                                           
 
2. ION CHANNEL DISEASES: 
GENETICS AND CARDIAC CHANNELOPATHIES                                            Pag.11                                                                                                                       
2.1 Diseases of Automaticity                                                                                              Pag.12                                           
2.2 HCN4 Diseases of Automaticity                                                                                  Pag.14                                           
2.3 Sick sinus syndrome                                                                                                     Pag.15                                           
 
3. DISEASES ASSOCIATED WITH SODIUM CHANNEL DYSFUNCTION         Pag.17                                                                                                                                                                                 
3.1 Brugada syndrome                                                                                                    Pag.19                                          
3.2 Lev-Lenegre syndrome                                                                                                  Pag.23                                           
3.3 Long QT Syndrome                                                                                                      Pag.24                                           
 
4. DISEASES ASSOCIATED WITH POTASSIUM CHANNEL DYSFUNCTION  Pag.30                                                                                                                                
4.1 Atrial fibrillation                                                                                                           Pag.31                                           
 
5. DISEASES ASSOCIATED WITH CALCIUM CHANNEL DYSFUNCTION        Pag.32  
5.1 Catecholaminergic polymorphic ventricular tachycardia                                             Pag.33                                           
 
6. MOLECULAR GENETIC RESULTS                                                                               Pag.34                                           
 
7. CONCLUSION                                                                                                                   Pag.48                                           
 
 
 
 
 
